International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
By S. Rajkumar, M. Dimopoulos, A. Palumbo, J. Bladé, G. Merlini, M. Mateos, Shaji K. Kumar, J. Hillengass, E. Kastritis, P. Richardson and 24 more. The Lancet Oncology, 2014
4,253 citations recorded by the source corpus.
Subfields: Hematology, Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/405d76f1b55c24bec827a96e92acefeddfde8676
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Hematology
In Molecular Biology
In Oncology
Citations in the corpus
- Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management (2020, methodology): “Source: Reproduced from Rajkumar et al.(1) 550 RAJKUMAR”
- Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. (2015, background): “The recent redefinition of smoldering myeloma based on distinct outcomes illustrates the potential for future reassessment of the nature of CHIP and MDS as additional data become available.(83)”
- Multiple myeloma: 2022 update on diagnosis, risk stratification, and management (2022, background): “Multiple myeloma accounts for 1% of all cancers and approximately 10% of all hematologic malignancies.(1,2) Each year, over 32 000 new cases are diagnosed in the United States, and almost 13 000 patients die of the disease.”
- KDIGO Clinical Practice Guideline on the Evaluation and Management of Candidates for Kidney Transplantation. (2020, methodology): “Guidelines from the International Myeloma Working Group suggest candidates with smouldering multiple myeloma and renal lesions should not be regarded as having myeloma defining events and do not warrant immediate myeloma treatment.(515) Currently, there is no consensus regarding the definitive treat”